Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026286 · ClinicalTrials.gov registry record · Phase 3
Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00026286: Completed Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
NCT00026286 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00026286, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Hormone replacement therapy may be effective in managing the hot flashes and/or vaginal symptoms in postmenopausal women who are receiving tamoxifen for breast cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of hormone replacement therapy in managing hot flashes and/or vaginal symptoms in postmenopausal women who are receiving tamoxifen for breast cancer.
Interventions
- DRUG medroxyprogesterone
- DRUG conjugated estrogens
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-11-28 |
| Est. Completion | 2007-06-15 |
| Phase | Phase 3 |
What the finished NCT00026286 record still lists
NCT00026286 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which medroxyprogesterone is the first listed.
NCT00026286 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00026286 about?
NCT00026286 is a clinical study titled "Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer". RATIONALE: Hormone replacement therapy may be effective in managing the hot flashes and/or vaginal symptoms in postmenopausal women who are receiving tamoxifen for breast cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of hormone replacement therapy in managing hot flashe...
What is the current status of trial NCT00026286?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-11-28. Estimated completion is 2007-06-15.
What interventions are being tested in trial NCT00026286?
The interventions under investigation include: medroxyprogesterone (DRUG), conjugated estrogens (DRUG).
Who is sponsoring clinical trial NCT00026286?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI